Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by BrokenPromison Apr 21, 2021 12:29pm
122 Views
Post# 33037555

RE:RE:RE:RE:RE:RE:IMMUSAFE.COM

RE:RE:RE:RE:RE:RE:IMMUSAFE.COMM101 - I bought into the "Promise" of best-in-class a couple of years ago.  I have what for me is a lot of money in this company.  Some of it as high as $0.42 usd.  I used to believe them when they talked about clinical trials.  I was also excited when they talked about the JV.  But the absolute reality is that the ONLY delivery so far has been a dilution.  So, I am a true skeptic.  I have heard the same pitch report after report about when Phase One starts:  "maana" which is an undefined, fuzzy sort of time that we don't really want to pin down.  So yeah, BrokenPromis.  I will change it when it is earned.  And hence my skepticism about this JV.  I TRULY hope it's real, because so far I have lost a bunch of money I really didn't want to lose, but I have held in there.  I will probably hold in until it goes to zero...
<< Previous
Bullboard Posts
Next >>